Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2026)

Cytek Biosciences has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 0.53% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 2.45% YoY), and the FY2025 full-year result was $7.6 million, up 5.09% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.9 million, down from $1.9 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.9 million in Q3 2025, with the low at $72000.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 61.9% — and 2023, when it jumped 2354.17%.
• Cytek Biosciences' Depreciation & Amortization (CF) stood at $761000.0 in 2022, then surged by 114.32% to $1.6 million in 2023, then increased by 13.67% to $1.9 million in 2024, then advanced by 2.27% to $1.9 million in 2025, then decreased by 1.64% to $1.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.